[go: up one dir, main page]

AR118650A1 - Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas - Google Patents

Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas

Info

Publication number
AR118650A1
AR118650A1 ARP200101025A ARP200101025A AR118650A1 AR 118650 A1 AR118650 A1 AR 118650A1 AR P200101025 A ARP200101025 A AR P200101025A AR P200101025 A ARP200101025 A AR P200101025A AR 118650 A1 AR118650 A1 AR 118650A1
Authority
AR
Argentina
Prior art keywords
solubilized
formulations
amorphas
plasma concentrations
enhanced performance
Prior art date
Application number
ARP200101025A
Other languages
English (en)
Inventor
Narayan Swamy Panduranga
Roopa Narasimhamurthy
Shabeerali Pattasseri
Sharmistha Pal
Gajendra Singh Chowan
Srikanth Koravady Sridhar
Ajay Saxena
Theresa M Ziemba
Vrushali M Waknis
Kevin J Stefanski
Jay Poorna Reddy
Jaquan Kalani Levons
Robert J Garmise
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR118650A1 publication Critical patent/AR118650A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta se refiere a dispersiones sólidas amorfas que comprenden el Compuesto (I) que tiene la fórmula (1) y uno o más polímeros o formulaciones de solución que comprenden el Compuesto (I) y uno o más codisolventes y tensioactivos. Las formulaciones exhiben una mayor estabilidad y biodisponibilidad.
ARP200101025A 2019-04-11 2020-04-13 Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas AR118650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11

Publications (1)

Publication Number Publication Date
AR118650A1 true AR118650A1 (es) 2021-10-20

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101025A AR118650A1 (es) 2019-04-11 2020-04-13 Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas

Country Status (18)

Country Link
US (1) US12509461B2 (es)
EP (1) EP3953355A1 (es)
JP (2) JP2022526656A (es)
KR (1) KR20210151183A (es)
CN (1) CN113924300A (es)
AR (1) AR118650A1 (es)
AU (2) AU2020271103B2 (es)
BR (1) BR112021020257A2 (es)
CA (1) CA3132530A1 (es)
CL (1) CL2021002627A1 (es)
CO (1) CO2021015054A2 (es)
EA (1) EA202192753A1 (es)
IL (1) IL287103A (es)
MX (2) MX2021012288A (es)
PE (1) PE20212367A1 (es)
SG (1) SG11202111131VA (es)
TW (1) TW202104228A (es)
WO (1) WO2020210629A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212644A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
MX2024002857A (es) 2021-09-17 2024-03-21 Bristol Myers Squibb Co Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.
JP2025525915A (ja) 2022-08-01 2025-08-07 ブリストル－マイヤーズ スクイブ カンパニー 虚血性脳卒中を処置又は予防するためのミルベクシアンの使用
AU2024217663A1 (en) 2023-02-06 2025-06-05 Bristol-Myers Squibb Company Milvexian pharmaceutical compositions
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83812B (en) 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
BR112016015717B1 (pt) * 2014-01-31 2023-04-04 Bristol-Myers Squibb Company Compostos macrociclos com grupos p2' heterocíclicos como inibidores do fator xia, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
HRP20200673T1 (hr) 2016-04-22 2020-07-10 Astrazeneca Ab Makrociklički inhibitori mcl1 za liječenje raka

Also Published As

Publication number Publication date
IL287103A (en) 2021-12-01
SG11202111131VA (en) 2021-11-29
CL2021002627A1 (es) 2022-05-06
EA202192753A1 (ru) 2022-01-11
US12509461B2 (en) 2025-12-30
KR20210151183A (ko) 2021-12-13
AU2020271103B2 (en) 2026-01-08
TW202104228A (zh) 2021-02-01
JP2022526656A (ja) 2022-05-25
BR112021020257A2 (pt) 2021-12-07
CN113924300A (zh) 2022-01-11
CO2021015054A2 (es) 2021-11-19
JP2025131625A (ja) 2025-09-09
AU2025279715A1 (en) 2026-01-15
EP3953355A1 (en) 2022-02-16
US20220144835A1 (en) 2022-05-12
MX2025011559A (es) 2025-11-03
MX2021012288A (es) 2021-11-12
CA3132530A1 (en) 2020-10-15
AU2020271103A1 (en) 2021-12-02
PE20212367A1 (es) 2021-12-21
WO2020210629A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
AR118650A1 (es) Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
CO2022002634A2 (es) Formas cristalinas de moduladores del cftr
JOP20180123A1 (ar) مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية
DOP2018000241A (es) Derivados aromáticos de sulfonamida
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
UY35362A (es) Compuestos terapéuticos
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
HN2012001162A (es) Triazolopiridinas
CO2018007669A2 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
UY35300A (es) Formulación de combinación de dos compuestos antivirales
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CO2021007453A2 (es) Conjugados de insulina
MX390814B (es) Compuestos y metodos para el tratamiento de enfermedades parasitarias.
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
CO2019003632A2 (es) Formulaciones de buprenorfina de liberación sostenida
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso
AR109409A1 (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso
AR106375A1 (es) Formulaciones para activar mosquitos